MER-102
MER-102 is in Phase I development for the treatment of deep vein thrombosis (DVT).
MER-102 is an oral low molecular weight heparin (LMWH) using Merrion's GIPET technology. It has been prepared in both tablet and capsule dosage forms. Typically all LMWH products are administered by injection and this limits the market potential of these products. Nonetheless, the current market for these products as injectables is $3 billion. Since LMWHs have the broadest safety margins of any anticoagulant therapy, the development of an oral dosage form would be of additional significant benefit to patients requiring long term prophylaxis for high risk of deep vein thrombosis, acute coronary syndrome, pulmonary embolism, and major orthopaedic surgery. MER-102 has completed several successful Phase I clinical trials.
Merrion is seeking a partner for the development and commercialisation of MER-102.
